REG - ValiRx PLC - Appointment of Joint Broker <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

07/06/2016 07:07

RNS Number : 3730A
ValiRx PLC
07 June 2016
ValiRx Plc
('ValiRx' or the 'Company')
Appointment of Joint Broker
London, UK, 7 June 2016: ValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine, announces that Beaufort Securities Limited has been appointed Joint Broker to the Company with immediate effect.
Dr Satu Vainikka, CEO of ValiRx plc, commented:"We have appointed Beaufort to assist us in particular with managing and communicating with our retail shareholder base and believe their knowledge of, and engagement with, UK retail investors will benefit the Company as we progress with the VAL201 and VAL401 clinical trials".
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray



Northland Capital Partners Limited (Joint Broker)
Tel: +44 (0) 203 861 6625
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)



Beaufort Securities Limited (Joint Broker)
Tel: +44 (0) 207 382 8300
Jon Belliss

Notes for Editors 
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken todevelop a novel and groundbreaking class of therapeutics across a number offields in oncology and has taken its lead compound, VAL201, into Phase I/IIclinicaltrials. The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases.
It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimising financial exposure andrunning a set of projects todefined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Reprofiling Ltd to develop VAL401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
APPKMGGVRVLGVZM